IGC Pharma Inc (IGC)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-06-30 2024-12-31 2024-09-30 2024-06-30
Revenue 328,000 257,000 412,000 272,000
Cost of Revenue 174,000 153,000 214,000 109,000
Gross Profit 154,000 104,000 198,000 163,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 1,208,000 1,130,000 1,041,000 1,670,000
Operating Expenses 2,059,000 1,982,000 1,958,000 2,559,000
Operating Income -1,905,000 -1,878,000 -1,760,000 -2,396,000
Interest Expense 0 0 0 0
Income Before Tax -1,599,000 -1,829,000 -1,717,000 -2,378,000
Income Tax Expense 0 0 0 0
Net Income -1,599,000 -1,829,000 -1,717,000 -2,378,000
Per Share
EPS -0.02 -0.02 -0.02 -0.03
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Revenue 1,271,000 1,345,000 911,000 397,000 898,000
Cost of Revenue 652,000 612,000 469,000 203,000 785,000
Gross Profit 619,000 733,000 442,000 194,000 113,000
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 4,410,000 6,758,000 8,552,000 13,292,000 7,908,000
Operating Expenses 8,065,000 10,531,000 12,013,000 15,622,000 8,837,000
Operating Income -7,446,000 -9,798,000 -11,571,000 -15,428,000 -8,724,000
Interest Expense 0 0 0 -412,000 0
Income Before Tax -7,121,000 -13,000,000 -11,506,000 -15,016,000 -8,811,000
Income Tax Expense 0 0 -65,000 -412,000 0
Net Income -7,121,000 -13,000,000 -11,506,000 -14,604,000 -8,811,000
Per Share
EPS -0.09 -0.22 -0.22 -0.29 -0.21
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Assets
Cash and Cash Equivalents 405,000 1,198,000 3,196,000 10,460,000
Short Term Investments 0 0 154,000 0
Net Receivables 77,000 39,000 131,000 597,000
Inventory 1,360,000 1,540,000 2,651,000 3,548,000
Total Current Assets 2,896,000 3,705,000 6,466,000 15,111,000
Property Plant Equipment 3,318,000 3,893,000 8,539,000 9,870,000
Goodwill and Intangibles 1,852,000 1,616,000 1,170,000 917,000
Total Assets 8,747,000 9,902,000 17,178,000 26,834,000
Liabilities
Account Payables 883,000 773,000 530,000 981,000
Short Term Debt 94,000 124,000 133,000 3,000
Total Current Liabilities 2,257,000 2,340,000 1,898,000 2,441,000
Long Term Debt 144,000 221,000 348,000 485,000
Total Liabilities 2,417,000 2,581,000 2,267,000 2,942,000
Shareholders Equity
Retained Earnings -120,744,000 -113,665,000 -100,665,000 -89,159,000
Total Shareholders Equity 6,330,000 7,321,000 14,911,000 23,892,000
Balance Sheet (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Assets
Cash and Cash Equivalents 405,000 1,198,000 3,196,000 10,460,000 14,548,000
Short Term Investments 0 0 154,000 0 80,000
Net Receivables 77,000 39,000 131,000 597,000 1,916,000
Inventory 1,360,000 1,540,000 2,651,000 3,548,000 5,478,000
Total Current Assets 2,896,000 3,705,000 6,466,000 15,111,000 23,517,000
Property Plant Equipment 3,318,000 3,893,000 8,539,000 9,870,000 11,328,000
Goodwill and Intangibles 1,852,000 1,616,000 1,170,000 917,000 407,000
Total Assets 8,747,000 9,902,000 17,178,000 26,834,000 35,867,000
Liabilities
Account Payables 883,000 773,000 530,000 981,000 476,000
Short Term Debt 94,000 124,000 133,000 3,000 304,000
Total Current Liabilities 2,257,000 2,340,000 1,898,000 2,441,000 2,368,000
Long Term Debt 144,000 221,000 348,000 485,000 681,000
Total Liabilities 2,417,000 2,581,000 2,267,000 2,942,000 3,064,000
Shareholders Equity
Retained Earnings -120,744,000 -113,665,000 -100,665,000 -89,159,000 -74,143,000
Total Shareholders Equity 6,330,000 7,321,000 14,911,000 23,892,000 32,803,000
Cash Flow Statement (Quarterly) 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Activities
Net Income -7,121,000 -13,000,000 -11,506,000 -15,016,000
Depreciation & Amortization 618,000 637,000 657,000 651,000
Stock Based Compensation 1,640,000 1,773,000 2,843,000 2,197,000
Change in Working Capital -72,000 1,894,000 794,000 2,536,000
Operating Cash Flow -4,795,000 -5,199,000 -7,047,000 -7,462,000
Investing Activities
Capital Expenditure -482,000 -515,000 -619,000 -742,000
Investments -112,000 -138,000 -619,000 -742,000
Investing Cash Flow -442,000 -317,000 -235,000 -742,000
Financing Activities
Debt Repayment -3,000 -3,000 -3,000 -3,000
Common Stock Issued/Repurchased 4,454,000 3,527,000 103,000 4,145,000
Dividends Paid 0 0 0 0
Financing Cash Flow 4,451,000 3,524,000 100,000 4,142,000
Summary
Free Cash Flow -5,277,000 -5,714,000 -7,666,000 -8,204,000
Net Change in Cash -793,000 -1,998,000 -7,264,000 -4,088,000
Cash Flow Statement (Annual) 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Operating Activities
Net Income -7,121,000 -13,000,000 -11,506,000 -15,016,000 -8,811,000
Depreciation & Amortization 618,000 637,000 657,000 651,000 478,000
Stock Based Compensation 1,640,000 1,773,000 2,843,000 2,197,000 658,000
Change in Working Capital -72,000 1,894,000 794,000 2,536,000 -3,294,000
Operating Cash Flow -4,795,000 -5,199,000 -7,047,000 -7,462,000 -10,800,000
Investing Activities
Capital Expenditure -482,000 -515,000 -619,000 -742,000 -1,592,000
Investments -112,000 -138,000 -619,000 -742,000 -1,470,000
Investing Cash Flow -442,000 -317,000 -235,000 -742,000 3,387,000
Financing Activities
Debt Repayment -3,000 -3,000 -3,000 -3,000 -50,000
Common Stock Issued/Repurchased 4,454,000 3,527,000 103,000 4,145,000 14,158,000
Dividends Paid 0 0 0 0 0
Financing Cash Flow 4,451,000 3,524,000 100,000 4,142,000 14,688,000
Summary
Free Cash Flow -5,277,000 -5,714,000 -7,666,000 -8,204,000 -12,392,000
Net Change in Cash -793,000 -1,998,000 -7,264,000 -4,088,000 7,290,000